Log In
BCIQ
Print this Print this
 

biosimilar cetuximab (ABP 494)

  Manage Alerts
Collapse Summary General Information
Company Allergan plc
DescriptionBiosimilar cetuximab, chimeric IgG1 mAb targeting EGFR
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionBinds epidermal growth factor (EGF) receptor; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/14/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today